New hope for inoperable bile duct cancer: targeted therapies aim to shrink tumors

NCT ID NCT06313203

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests two treatments for a type of bile duct cancer that cannot be surgically removed. One delivers chemotherapy directly to the liver through a pump, and the other uses tiny radioactive beads injected into the tumor's blood supply. Both are given alongside standard chemotherapy. The goal is to see if these combinations can shrink tumors enough to allow surgery or help patients live longer. About 39 people will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Floxuridine (via hepatic artery infusion) and Yttrium-90 radioactive particles (via selective internal radiation therapy)

What this could lead to

If successful, this could offer a way to shrink inoperable bile duct tumors enough for surgery, potentially improving survival and giving more patients a chance at a cure.

What could go wrong

This is a small, early-phase trial (39 people) without randomization, so results may not apply broadly. Both treatments have risks like liver damage or infection, and the floxuridine arm requires frequent hospital visits.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLANGIOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chemotherapy-induced toxicity cholangiocarcinoma intrahepatic cholangiocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Oslo University Hospital

    RECRUITING

    Oslo, Oslo, 0424, Norway

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••